Skip to main content
    C

    Codexis Inc (CDXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    -0.10 (-8.62%)

    Market Cap: $127.13M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Codexis Inc (CDXS) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Codexis (CDXS) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Codexis reported EPS of -$0.08, above the -$0.09 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    +18.31%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.18 - -$0.05
    9 analysts
    Revenue Consensus
    $25.11M
    Range$22.39M - $27.72M
    10 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.08
    Range-$0.10 - -$0.06
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.12+33.3%
    60d ago-$0.12+33.3%
    30d ago-$0.10+20.0%
    7d ago-$0.10+20.0%
    Current-$0.08
    Revenue Consensus
    $18.31M
    Range$16.20M - $21.97M
    5 analysts

    Next Report

    CDXS has an expected report date of Mar 9, 2027.

    CDXS Earnings Call

    The latest CDXS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CDXS beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $19.26M, up 124.0% from $8.60M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.08-$0.09-$0.11 - -$0.08+11.11%BeatN/A21 up, 0 downNov 12, 2026$19.26M
    Jun 30, 2026-$0.13-$0.17N/A+23.53%BeatN/A20 up, 1 downAug 11, 2026$14.91M
    Mar 31, 2026-$0.10-$0.10-$0.13 - -$0.080.00%In lineN/A20 up, 1 downMay 7, 2026$15.25M
    Dec 31, 2025$0.14-$0.04-$0.06 - -$0.01+485.44%BeatN/A21 up, 0 downMar 11, 2026$38.91M
    Sep 30, 2025-$0.22-$0.13-$0.15 - -$0.10-69.23%MissN/A31 up, 1 downNov 6, 2025$8.60M
    Jun 30, 2025-$0.16-$0.15-$0.18 - -$0.10-6.67%MissN/A31 up, 2 downAug 13, 2025$15.33M
    Mar 31, 2025-$0.25-$0.21-$0.24 - -$0.16-19.05%MissN/A40 up, 1 downMay 14, 2025$7.54M
    Dec 31, 2024-$0.13-$0.04-$0.06 - $0.05-225.00%MissN/A62 up, 2 downFeb 27, 2025$21.46M
    Sep 30, 2024-$0.29-$0.21-$0.26 - -$0.19-38.10%MissN/A81 up, 0 downOct 31, 2024$12.83M
    Jun 30, 2024-$0.32-$0.24N/A-33.33%MissN/A70 up, 0 downAug 8, 2024$7.98M
    Mar 31, 2024-$0.16-$0.14-$0.22 - -$0.14-14.29%MissN/A70 up, 1 downMay 2, 2024$17.07M
    Dec 31, 2023-$0.10-$0.12-$0.31 - -$0.03+16.67%BeatN/A70 up, 0 downFeb 28, 2024$26.56M
    Sep 30, 2023-$0.31-$0.26N/A-19.23%MissN/A70 up, 0 downNov 2, 2023$9.28M
    Jun 30, 2023-$0.17-$0.14-$0.30 - -$0.11-21.43%MissN/A84 up, 0 downAug 3, 2023$21.32M
    Mar 31, 2023-$0.34-$0.25N/A-36.00%MissN/A80 up, 0 downMay 4, 2023$12.98M
    Dec 31, 2022-$0.14-$0.23-$0.28 - -$0.18+39.13%BeatN/A80 up, 0 downFeb 23, 2023$30.37M
    Sep 30, 2022-$0.15-$0.16-$0.22 - -$0.12+6.25%Beat-600.0%80 up, 0 downNov 3, 2022$34.47M
    Jun 30, 2022-$0.04-$0.12-$0.18 - -$0.08+66.67%BeatN/A81 up, 1 downAug 4, 2022$38.41M
    Mar 31, 2022-$0.13-$0.15-$0.20 - -$0.15+13.33%BeatN/A80 up, 0 downMay 5, 2022$35.34M
    Dec 31, 2021-$0.16-$0.22-$0.26 - -$0.17+27.27%BeatN/A7N/AFeb 24, 2022$24.50M
    Sep 30, 2021$0.03-$0.05N/A+160.00%BeatN/A84 up, 0 downNov 4, 2021$36.77M
    Jun 30, 2021-$0.01-$0.12N/A+91.67%BeatN/A8N/AAug 5, 2021$25.45M
    Mar 31, 2021-$0.09-$0.18-$0.26 - -$0.11+50.00%BeatN/A8N/AMay 6, 2021$18.03M
    Dec 31, 2020-$0.06-$0.12-$0.15 - -$0.08+50.00%Beat-400.0%6N/AFeb 25, 2021$36.00M
    Sep 30, 2020-$0.06-$0.05N/A-20.00%Miss-250.0%6N/ANov 5, 2020$18.39M
    Jun 30, 2020-$0.07-$0.13-$0.28 - -$0.13+46.15%BeatN/A6N/AAug 6, 2020N/A
    Mar 31, 2020-$0.13-$0.15-$0.19 - -$0.09+13.33%BeatN/A5N/AMay 7, 2020$14.67M
    Dec 31, 2019$0.02$0.05N/A-60.00%MissN/A4N/AFeb 27, 2020$18.65M
    Sep 30, 2019$0.04-$0.05N/A+180.00%BeatN/A4N/ANov 5, 2019$21.91M
    Jun 30, 2019-$0.08-$0.07-$0.14 - -$0.04-14.29%MissN/A3N/AAug 6, 2019$12.32M
    Mar 31, 2019-$0.05-$0.08-$0.13 - -$0.04+37.50%BeatN/A5N/AMay 6, 2019$15.58M
    Dec 31, 2018-$0.01-$0.03-$0.05 - $0.00+66.67%Beat-150.0%5N/AFeb 26, 2019$16.07M
    Sep 30, 2018-$0.04-$0.03N/A-33.33%MissN/A5N/ANov 8, 2018$16.95M
    Jun 30, 2018-$0.02-$0.08N/A+75.00%BeatN/A5N/AAug 8, 2018$13.54M
    Mar 31, 2018-$0.05-$0.08N/A+37.50%BeatN/A3N/AMay 10, 2018$14.04M
    Dec 31, 2017$0.02$0.05$0.03 - $0.08-60.00%MissN/A3N/AMar 8, 2018$21.72M
    Sep 30, 2017-$0.21-$0.15N/A-40.00%Miss-800.0%3N/ANov 9, 2017$9.98M
    Jun 30, 2017-$0.13-$0.12-$0.14 - -$0.12-8.33%Miss-360.0%3N/AAug 9, 2017$10.35M
    Mar 31, 2017-$0.18-$0.14N/A-28.57%MissN/AN/AN/AMay 9, 2017$7.97M
    Dec 31, 2016-$0.13-$0.11N/A-18.18%MissN/AN/AN/AMar 9, 2017$9.97M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.49, after -$0.90 the year before. It was -$0.22 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.49N/A
    Dec 31, 2024-$0.90N/A
    Dec 31, 2023-$0.92N/A
    Dec 31, 2022-$0.46N/A
    Dec 31, 2021-$0.23N/A
    Dec 31, 2020-$0.32N/A
    Dec 31, 2019-$0.07N/A
    Dec 31, 2018-$0.12N/A
    Dec 31, 2017-$0.50N/A
    Dec 31, 2016-$0.22N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,26012
    2026Q2Jun 30, 20265,09011
    2026Q1Mar 31, 20264,0649
    2025Q4Dec 31, 20255,3239
    2025Q3Sep 30, 20253,1018
    2025Q2Jun 30, 20254,5169
    2025Q1Mar 31, 20254,97111
    2024Q4Dec 31, 20247,31912

    2026Q3 Earnings Call

    Opening remarks

    Georgia Erbez Chief Financial Officer and Chief Business Officer Thank you, operator. With me today are Alison Moore, President and Chief Executive Officer; Stefan Lutz, Chief Scientific Officer; and Britton Jimenez, Senior Vice President, Sales and Marketing. During this call, management will make a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones and product launches, facility expansions, technical milestones and public announcements related thereto, as well as our strategies and prospects for revenue growth and successful execution of current and future programs and partnerships. To the extent these statements contained in the call are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, November 12, 2026. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis' filings with the Securities and Exchange Commission. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. And now I'll turn the call over to Alison.

    Alison Moore President and Chief Executive Officer Thank you, Georgia, and thanks, everyone, for joining the call. Codexis generates manufacturing solutions using highly engineered enzymes. The use of biocatalysis in the pharmaceutical industry has dramatically advanced the production of complex small molecule therapeutics, and we are now focused on delivering a significantly improved enzymatic production system to manufacture oligonucleotide medicines. As we enter the final quarter of 2026, I am very proud of our accomplishments so far. Today, we reported solid third quarter results with revenues of $19.3 million, our fourth consecutive quarterly on-target performance. Early in the quarter, we completed an equity offering in which we raised $25 million of net proceeds. In addition, this week, we announced we entered into a $60 million term loan agreement, of which $42.5 million was used in an initial drawdown to replace an existing loan. This combination of strong operating performance, bolstering our cash balance and deferring our debt repayment has strengthened our financial position as we complete the year. Georgia will give us more details on our financial achievements later in the call. 2026 has been a year of recognition for the developers of RNAi medicines, recognition of the huge therapeutic opportunity in large-population indications and also recognition that traditional manufacturing methods are insufficient to support the commercial aspirations of these important new medicines. Exploration of enzymatic approaches is building significantly, and Codexis' ECO Synthesis platform is in the lead in defining alternative approaches.

    Frequently Asked Questions About CDXS

    When is Codexis's next earnings date?

    Codexis's next earnings report is expected for Mar 9, 2027.

    Did CDXS beat earnings estimates last quarter?

    Yes. Codexis reported EPS of -$0.08 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 11.11% surprise.

    What EPS do analysts expect from CDXS next quarter?

    The consensus EPS estimate for Codexis for the quarter ending Dec 31, 2026 is -$0.09 from 9 analysts, with estimates from -$0.18 to -$0.05.

    How often does CDXS beat earnings estimates?

    Codexis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +25.02%.